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ABSTRACT 
Objective 
In the era of damage control resuscitation of trauma patients with acute major 
haemorrhage, transfusion practice has evolved to blood component 
(component therapy) administered in a ratio that closely approximates whole 
blood (WB). However, there is a paucity of evidence supporting the optimal 
transfusion strategy in these patients. The primary objective was therefore to 
establish if there is an improvement in survival at 30-days with the use of WB 
transfusion compared with blood component therapy in adult trauma patients 
with acute major haemorrhage. 
 
Methodology 
A systematic literature search was performed on the 15th December 2019 to 
identify studies comparing WB transfusion with component therapy in adult 
trauma patients and mortality at 30 days. Studies which did not report 
mortality were excluded. Methodological quality of included studies was 
interpreted using the Cochrane risk of bias tool, and rated using the Grading 
of Recommendations Assessment, Development and Evaluation (GRADE) 
approach.  
 
Results 
Search of the databases identified 1885 records, and six studies met the 
inclusion criteria involving 3255 patients. Of the three studies reporting 30-day 
mortality (one RCT (moderate evidence) and two retrospective (low and very 
low evidence respectively)), only one study demonstrated a statistically 
significant difference between WB and component therapy, and two found no 
statistical difference. Two retrospective studies reporting in-hospital mortality 
found no statistical difference in unadjusted mortality, but both reported 
statistically significant logistic regression analyses demonstrating that those 
with a WB transfusion strategy were less likely to die.  
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Conclusion 
Recognising the limitations of this systematic review relating to the poor-
quality evidence and limited number of included trials, it does not provide 
evidence to support or reject use of WB transfusion compared with 
component therapy for adult trauma patients with acute major haemorrhage.  
 
 
 
  
Key messages 
What is already known on this subject 
• Transfusion practice in trauma has evolved to administration of blood 
component therapy (red cells, plasma and platelets) in a ratio that 
closely approximates whole blood. 
• However, it has not been determined if whole blood vs. component 
therapy is superior. 
 
What this study adds 
• In this systematic review, we found six studies directly addressing WB 
vs. component therapy. Overall level of evidence was very low to 
moderate with only 1 RCT. No studies reported worse survival with 
whole blood, however, there is insufficient evidence to support or 
reject the use of whole blood transfusion compared with component 
therapy for adult trauma patients with acute major haemorrhage.  
• Larger prospective, randomised or adaptive trials are required to better 
understand if whole blood improves survival in adult trauma patients 
with acute major haemorrhage compared with component therapy.  
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BACKGROUND    
Death from traumatic injury is a leading cause of life-years lost worldwide.(1-
3) In 2010 there were more deaths from injuries (5.1 million) than HIV-AIDS, 
tuberculosis and malaria combined (3.8 million).(4) Around 40% of trauma 
deaths result from uncontrolled haemorrhage with the majority of patients 
dying within the first 24 hours after injury.(5, 6)  
 
Blood banks were pioneered during the First World War and fresh whole 
blood was the preferred product for resuscitating trauma patients in 
haemorrhagic shock.(7) Whole blood (WB) can be transfused fresh within 24 
hours of donation, or cold-stored for up to 35 days depending on the additive 
solution. (8, 9) In military settings, fresh WB remained the primary 
resuscitation fluid until the 1960s when advances were made in blood 
component separation.(10) Blood component therapy has become the 
predominant transfusion approach in middle and high income countries as the 
extension of shelf-life provided a more manageable approach for blood 
services. This change in transfusion strategy occurred without evidence to 
compare the efficacy and risks of WB compared with component therapy in 
patients with acute major haemorrhage.(11) Leucoreduction techniques have 
since been developed with improved clinical outcomes in non-haemolytic 
transfusion reactions, disease transmission, and HLA alloimmunisation.(12) 
 
Over the last ten years, damage control resuscitation principles have gained 
wide acceptance in civilian practice for trauma patients with acute major 
bleeding, based on prevention and correction of trauma-induced coagulopathy 
and rapid haemorrhage control. Evidence suggests that trauma-induced 
coagulopathy is a multifactorial failure of coagulation due to endogenous 
acute traumatic coagulopathy (13) and dilutional resuscitation-induced 
coagulopathy.(14) 
 
The damage control resuscitation approach promotes early transfusion of red 
blood cells, plasma and platelets in a 1:1:1 ratio, rapid surgical control of 
ongoing bleeding and prevention of acidosis and hypothermia.(15-18) 
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Hypotensive resuscitation is advocated until bleeding control is achieved.(19) 
Of note, patients with traumatic brain injury (TBI) are not generally 
resuscitated with permissive hypotension as they require a higher mean 
arterial pressure to maintain cerebral perfusion. Damage control resuscitation 
efforts are focused on minimising the impact of trauma-induced coagulopathy 
by limiting the use of crystalloid and transfusing blood component in a ratio 
that closely approximates WB. The United States Tactical Combat Casualty 
Care guidelines published in 2017 and 2018 advocate the use of WB 
transfusion.(20, 21) WB contains the individual component in a smaller 
transfusion volume with increased haematocrit and fibrinogen, reducing the 
total non-haemostatic, non-oxygen carrying fluid transfused into a trauma 
patient. Theoretically, use of WB may correct acute traumatic coagulopathy 
more efficiently than component therapy due to the simultaneous infusion of 
platelets and plasma with the red cells, which when administered together 
may reduce mortality and transfusion requirements.(22)  
 
Despite changes in transfusion practice in trauma patients, there is a paucity 
of evidence to guide the optimal transfusion strategy for blood component in 
trauma. Recent military experience suggests that WB may be the optimum 
transfusion strategy; however, no systematic review has been conducted to 
date.(19)  
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METHODOLOGY      
We performed a systematic review of studies comparing WB to component 
therapy in adult trauma patients with acute major haemorrhage. Our primary 
outcome was survival at 30-days. Secondary outcomes were in-hospital 
mortality, 24-hour mortality, total volume of transfusion, morbidity including 
Acute Respiratory Distress Syndrome (ARDS), Acute Kidney Injury (AKI), 
Multiple Organ Dysfunction Syndrome (MODS), embolic events and 
transfusion reactions. 
 
This systematic review was carried out in accordance with to the Preferred 
Reporting Items for Meta-Analyses (PRISMA) guidelines (23) and was 
prospectively entered onto the PROSPERO register (CRD42019131406).(24) 
 
Electronic database searching was carried out in line with PRISMA guidelines. 
PubMed, Web of Science, Cochrane, OVID, Embase and the Transfusion 
Evidence Library were searched independently by two reviewers (PA and SM) 
using MESH terms combined with the Boolean operator ‘AND’ (Table 1). The 
search dates start from the inception of the databases to the search date (15th 
December 2019). Non-English language papers, abstracts and other non-
published data were excluded; abstracts and non-published data were 
excluded to ensure the included literature had been peer-reviewed.  
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Terms for whole blood 
blood OR blood transfusion OR whole blood OR whole blood transfusion OR blood 
banks OR blood bank OR blood* 
Terms for component therapy 
blood component transfusion OR component therapy OR blood transfusion OR 
platelets OR plasma OR red blood cells OR red cells OR erythrocyte transfusion OR 
packed cell OR simple cell 
Terms for haemorrhagic shock 
exsanguination OR acute haemorrhage OR acute bleeding OR haemorrhagic shock 
OR haemorrhage OR acute major haemorrhage OR code red 
Terms for adult 
adult 
Terms for trauma patients 
trauma OR polytrauma OR blunt trauma OR penetrating trauma OR wounds OR 
injuries 
Terms for types of trials 
retrospective OR prospective OR randomised OR randomised controlled OR 
observational OR cohort studies OR RCT OR randomised* 
Terms for outcomes 
morbidity OR mortality OR multiorgan failure OR organ failure OR sepsis OR 
transfusion reaction OR adult respiratory distress syndrome OR myocardial infarction 
OR pulmonary embolus OR renal failure OR volume transfusion OR ARDS OR PE OR 
MI OR AKI OR acute kidney injury OR acute renal failure OR outcome OR outcomes 
OR thrombotic events OR immunological reactions 
Table 1 Electronic database search terms combined with Boolean operator 'AND' 
 
Titles and abstracts were uploaded to EndNote X7, duplicates were removed 
and relevant titles were selected by two independent reviewers (PA and SM). 
Where indicated, full text papers were reviewed for inclusion or exclusion 
based on clear criteria (Table 2). Reference lists were screened for relevant 
titles. Authors of three included studies were contacted to clarify the time point 
of recorded ‘mortality’ and to request missing data, but no replies were 
received.(8, 25, 26) For studies deemed relevant by abstract the full text 
report was retrieved and examined further for compliance with the inclusion 
criteria. There were no relevant unpublished materials or conference abstracts 
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excluded because they lacked a full report, and no disagreements between 
the two independent reviewers about the inclusion of studies.  
 
 Inclusion criteria Exclusion criteria 
Study 
design 
Randomised controlled trials 
comparing the effects of whole 
blood vs. component therapy 
between two groups or more. 
Prospective or retrospective 
observational cohort studies. 
Unpublished material (PhD/MSc 
thesis), letters to the editor, 
reviews and conference 
abstracts. 
Participants Human subjects aged ≥16 years 
requiring emergent 
uncrossmatched blood following 
traumatic injury 
 
<16 years 
Animal or cadaveric studies 
Outcome Reported outcomes of 30-day 
mortality and/or in-hospital 
mortality, 24-hour mortality, total 
volume of units transfused, 
morbidity including ARDS, AKI, 
MODS, embolic events and 
transfusion reactions. 
Mortality not reported as an 
outcome  
Language English language papers Non-English language papers  
Table 2 Inclusion and exclusion criteria 
 
Records of each database search were kept, the date, total number of hits, 
number of duplicates removed, number excluded based on title, number 
excluded based on abstract and full text for each reviewer. All titles were 
stored on EndNote X7.  
 
The two reviewers (PA and SM) extracted data independently into Excel. 
Extracted information included: authors, year, title, country, study design, 
study setting, time period, number of participants, study population, primary 
outcome measure, secondary outcome measures, inclusion and exclusion 
criteria, details of whole blood transfusion, details of component therapy, 
mortality at 30-day or in-hospital, mortality at 24-hour (if reported), TBI (if 
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reported), and study conclusions. Information collected for risk of bias 
assessment for individual study methodology and reporting included: 
participant selection, participant and allocation concealment, handling of 
incomplete outcome data, and outcome reporting.  
 
Following data extraction, percentage of 30-day or in hospital mortality was 
presented. Results from each study were defined as statistically significant if 
the p value was <0.05. Due to the diversity between the included study 
populations and interventions, pooling of outcome data for meta-analysis was 
not performed. Findings are presented narratively. 
 
The GRADE approach was used as a systematic method to rate the reliability 
of evidence from each included study.(27) As part of this, limitations of 
included study designs and execution were assessed using the Cochrane risk 
of bias tool. (28) Heterogeneity between included studies, indirectness and 
imprecision were assessed. Quality appraisal was carried out by both 
reviewers (PA and SM) independently. There were no disagreements 
between the reviewers regarding the risk of bias and GRADE rating. 
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RESULTS 
A summary of the literature search is shown in Figure 1. We screened 1551 
records after duplicates were removed, and 1477 were excluded by title. 65 
records were excluded by abstract and nine full texts were assessed for 
eligibility. Three full text articles were excluded as two were review articles, 
and one did not compare WB with component therapy. A total of six studies, 
involving 3255 patients, met the inclusion criteria. No ongoing studies or 
unpublished abstracts were identified at the time of search (15th December 
2019).  
 
Figure 1.  Summary of literature search  
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Included studies 
Setting 
Three studies were military based in Afghanistan and Iraq involving combat 
casualties (total n=1211).(26, 29, 30) The other three studies were conducted 
in the United States with civilian patients (total n=2044).(8, 25, 31) One 
civilian study included patients aged 15-91 years in their component therapy 
group.(8) All other included patients are ≥16 years. 
 
Interventions 
The studies incorporated a wide range of transfusion strategies. Each study 
looked at a transfusion approach involving WB and compared this to 
component therapy. There was considerable variation in the definition of WB 
transfusion and component. For example, Cotton et al. defined their WB 
transfusion as leucoreduced, modified WB with the addition of apheresis 
platelets for every six units.(31) Another study defined the WB group as 
receiving non-leucoreduced, warm fresh WB with red blood cells and 
plasma.(30) 
 
Trial design 
Two out of the six included studies were prospective: one prospective 
randomised trial (31), and the other prospective with historical controls.(8) The 
other four studies were retrospective analyses.(25, 26, 29, 30) 
 
All six studies reported mortality, four as a primary outcome measure (25, 26, 
29, 30), and two as a secondary outcome measure.(8, 31) 30-day and 24-
hour mortality was reported in three studies (29-31), with two others reporting 
in-hospital mortality (25, 26), and one reporting mortality with no further 
detail.(8)  
 
Three studies reported rates of ARDS (29-31), two reported rates of AKI (30, 
31), two reported rates of MODS (29, 31), and two reported rates of embolic 
events. (29, 30) Transfusion volumes are reported by four studies.(8, 26, 30, 
31) Three studies reported transfusion reactions.(8, 26, 31) 
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Risk of bias and quality appraisal 
Risk of bias interpretation is displayed in Table 3. A summary of author 
judgement is presented in Figure 2. 
 
Figure 2. Summary of risk of bias  
 
 
 
Selection bias was present in all six included studies. Four of these are 
retrospective with selection bias inherent in design. Selection bias was also 
present in the prospective, randomised trial resulted due to the lack of an 
objective scoring system to randomise patients.(31) Most studies reported 
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efforts to minimise attrition bias. Only one paper reported significant 
incomplete outcome data which may bias the result (if the unknown outcomes 
were poorer in one group), and limits the power to detect a statistical 
difference.(29) Due to important differences between studies in terms of 
populations, interventions, designs and outcome measures, we did not pool 
the data for meta-analysis. 
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Study Design 
Initial 
GRADE Risk of bias interpretation GRADE 
Cotton et al 
(31) 
Prospective, 
Randomised trial 
HIGH 
HIGH* 
• Selection bias: no objective scoring system to randomise patients 
• Performance bias: due to inadequate concealment of allocations 
• Detection bias: due to knowledge of the allocated interventions by outcome 
assessors 
• Study and clinical personnel unblinded to treatment group 
Serious 
limitations, 
downgrade one 
level 
MODERATE ⊕⊕⊕ 
Jones et al 
(25) 
Retrospective LOW 
HIGH* 
• Selection bias: retrospective study 
• Reporting bias: due to selective outcome reporting  
• WB not further qualified 
• Number of products transfused not reported 
• FFP not included 
Serious 
limitations, 
downgrade one 
level 
VERY LOW⊕ 
Nessen et al 
(26) 
Retrospective 
analysis of 
prospectively 
collected dataset 
LOW 
UNCLEAR** 
• Selection bias: retrospective convenience sample of those teams that had 
collected data introducing sampling bias 
• Survival bias: minimised by eliminating patients who died in first hour  
No serious 
limitations, do not 
downgrade 
LOW⊕⊕ 
Perkins et al 
(29) 
Retrospective review LOW 
HIGH* 
• Selection bias: retrospective study 
• Attrition bias: due to amount of incomplete outcome data, huge loss to 
follow up 
• Survival bias 
Serious 
limitations, 
downgrade one 
level 
VERY LOW⊕ 
Spinella et al 
(30) 
Retrospective LOW 
UNCLEAR** 
• Selection bias: retrospective study 
• Survival bias 
No serious 
limitations, do not 
downgrade 
LOW⊕⊕ 
Yazer et al 
(8) 
Prospective, historical 
controls 
LOW 
HIGH* 
• Selection bias: groups produced not directly comparable, significance 
difference in median age of patients, biased allocation to intervention 
Serious 
limitations, 
downgrade one 
level 
VERY LOW⊕ 
Table 3 Quality of evidence: GRADE rating with Cochrane risk of bias interpretation 
* HIGH: Plausible bias that seriously weakens confidence in the results. Crucial limitation for one criterion, or some limitations for multiple criteria, sufficient to lower confidence in the estimate of effect. 
** UNCLEAR: Plausible bias that raises some doubt about the results. 
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Effects of interventions (see Table 4) 
Primary outcome 
30-day mortality is the primary outcome of this systematic review, and three 
studies reported this data (n=830). Two studies, an RCT  by Cotton et al 
(grade of evidence Moderate), and retrospective study by Perkins et al (grade 
of evidence Very Low),  found no statistically significant  difference in 30-day 
mortality between whole blood transfusion strategy and blood component 
therapy.(29, 31) The third study, a retrospective study by Spinella et al (Grade 
of evidence Low) found a statistically significant difference in 30-day mortality 
between whole blood transfusion and component therapy (5% vs 18% 
respectively, p=0.002).(30) 
 
 
Secondary outcomes 
In-hospital mortality 
Two retrospective studies (Grade of evidence Very Low and Low) reported in-
hospital mortality and found no statistical difference in unadjusted mortality 
between groups (n=2233).(25, 26) However, logistic regression analyses of 
these studies found a statistically lower likelihood of death in patients 
receiving whole blood transfusion strategy (see Table 4). A prospective study 
with historical controls (Grade of evidence Low) reported ‘mortality’, but did 
not specify a measured time point, and showed no statistically significant 
difference between the two groups (n=192).(8) 
 
Twenty-four-hour mortality 
Three studies reported 24-hour mortality (n=830). Two studies found no 
statistically significant difference in 24-hour mortality between whole blood 
transfusion strategy and blood component therapy.(29, 31); the grade of 
evidence for these studies was Very Low (retrospective study) and Moderate 
(RCT). A third, retrospective study (n =354, Grade of evidence very low)) 
found a statistically significant difference in 24-hour mortality between whole 
blood transfusion and blood component therapy (4% vs 12% respectively, 
p=0.018).(30) 
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ARDS 
Three studies reported rates of ARDS. Two studies found no statistically 
significant difference between the two groups (30, 31), and one study found a 
higher incidence of ARDS in the fresh WB group compared to apheresis 
platelets (aPLT) group (18.8% vs 7.4% respectively, p=0.002).(29) 
 
Acute Kidney Injury  
Two studies reported the incidence of AKI. One study found no statistical 
difference in AKI between those receiving WB and those receiving component 
therapy.(31) One study reported a higher incidence of AKI in the group 
receiving WB transfusion compared to component therapy (8% vs 3% 
respectively, p=0.04).(30) 
 
Multiple Organ Dysfunction Syndrome  
Two studies reported rates of MODS. Neither study found a statistically 
significant difference in MODS between those receiving WB transfusion and 
those receiving component therapy.(29, 31) 
 
Embolic events 
Two studies reported rates of embolic events. Neither study found a 
statistically significant difference in embolic events between those receiving 
WB transfusion and those receiving component therapy.(29, 30) 
 
Number of units transfused 
Four studies reported volume of units transfused. Two studies found no 
statistical difference between the number of blood products received by each 
group.(8, 31) One study reported that actual blood volume transfused was 
higher in component therapy group compared to the WB group (6.8L vs 5.7L 
respectively, p=0.03).(30) One study found that FWB patients received 
significantly more units of both red blood cells and fresh frozen plasma.(26) 
 
Transfusion reactions 
Three studies reported on transfusion reactions. Two studies reported no 
transfusion reactions in patients receiving WB transfusion.(8, 26) One study 
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reported specifically no cases of transfusion-related acute lung injury in either 
group.(31) 
 
Sub-analysis of patients with TBI 
Only one study excluded patients with penetrating head injury and Glasgow 
Coma Score of ≤7.(26) One study performed a sensitivity analysis to assess 
outcomes of patients without severe TBI.(31) The authors found that WB 
significantly reduced transfusion volumes in patients without severe TBI, but 
there was no statistically significant difference in 30-day mortality (6% WB vs 
9% component therapy, p=0.62). This again may represent a type II error as 
the study was not powered to demonstrate a difference in 30-day mortality. 
Another study we examined conducted a post-hoc analysis excluding patients 
with TBI, and also found that use of WB significantly reduced the number of 
red blood cell and platelet transfusions.(8)  
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Study 
Number of 
participants 
Inclusion 
criteria 
Outcome measures Whole Blood 
Component 
Therapy 
Results 
Quality of the 
evidence 
(GRADE) 
Cotton et 
al. (2013) 
 
(31) 
107 
 
 > 18 years old, 
highest level 
trauma activation, 
active bleeding 
requiring uncross 
matched blood 
Primary: 24h blood product 
use 
 
Secondary: 24h mortality, 
30d mortality, length of stay, 
transfusion associated 
complications, infections  
mWB   
(leucoreduced) 
 
+ aPLT for every 
6 units 
RBC + plasma  
 
+ aPLT for 
every 6 units 
No statistical difference in 30-day mortality  
22% mWB vs 14% BCT (p=0.26) 
 
No statistical difference in 24-hour mortality  
11% mWB vs 10% BCT (p=0.83) 
 
No statistical difference in 24-hour component use 
(p=0.462) 
No other statistical differences between groups in 
ARDS, AKI, MODS 
MODERATE ⊕⊕⊕ 
Perkins et 
al. (2011) 
 
(29) 
369 
Trauma patients 
who required ≥10 
units of blood 
component 
transfused within 
first 24 hours and 
did not receive 
both FWB and 
aPLT 
Primary: Survival at 24h and 
30d 
 
Secondary: Rates of ARDS, 
MODS, infection, embolic 
events 
FWB (non-
leucoreduced)  
 
+ RBC + FFP + 
cryo 
aPLT + RBC + 
FFP + cryo 
No statistical difference in 30-day mortality 
43% FWB vs 40% aPLT (p=0.72) 
Note a large loss to follow up (20% FWB vs 37.6% 
aPLT) 
 
No statistical difference in 24-hour mortality  
19% FWB vs 16% aPLT group (p=0.52) 
 
Higher incidence of ARDS in FWB vs aPLT  
18.8% vs 7.4% (p=0.002) 
No statistical difference in MODS, embolic events 
 
Multivariate regression analysis of FWB vs aPLT 
24 hours OR 3.38, 95% CI 0.96-11.87 (p=0.06) 
30 days HR 1.38, 95% CI 0.77-2.47 (p=0.28) 
VERY LOW 
⊕ 
Spinella 
et al. 
(2009) 
 
(30) 
354 
Military combat 
patients in 
Afghanistan and 
Iraq who received 
at least 1 unit RBC 
and were treated 
at a level II or level 
III hospital. Those 
receiving both 
WFWB and aPLT 
were excluded. 
Primary: Survival at 24hr and 
30d 
 
Secondary: Blood product 
administration, adverse effects  
WFWB (non-
leucoreduced)  
 
+ RBC + plasma  
aPLT + RBC + 
plasma 
Statistically significant difference for both 24-
hour and 30-day mortality 
24-hour: WB 4% vs BCT 12% (p=0.018) 
30-day: WB 5% vs BCT 18% (p=0.002) 
Multivariate logistic regression analysis 
improved 30-day survival in WFWB group vs BCT 
group OR 12.4, 95% CI 1.8-80 (p=0.01). 
 
Increased AKI in WB (8%) vs BCT group (3%) 
(p=0.04).   
No statistical difference in ARDS or embolic 
events 
Actual blood volume transfused higher in BCT 
group (5.7L vs 6.8L, p=0.03) 
LOW 
⊕⊕ 
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Jones et 
al. (2014) 
 
(25) 
1745 
Age 18-45, 
ISS>25, required 
hospital 
admission, 
received blood 
transfusion 
Primary: In-hospital Mortality 
 
Secondary: Survival odds 
ratios 
WB  
(no additional 
information 
available) 
RBC + PLT 
No statistical difference in mortality  
21% WB vs 26% BCT (p=0.27) 
 
Logistic regression analysis  
BCT patients 3.2 times more likely to die vs 
WB  
OR 3.164, 95% CI: 1.314-7.618 (p=0.01) 
VERY LOW 
⊕ 
Nessen 
et al. 
(2013) 
 
(26) 
488 
Military combat 
patients in 
Afghanistan 
requiring treatment 
by the six studied 
US Forward 
Surgical Teams  
Primary: Mortality 
determined at inpatient 
discharge 
 
Secondary: Mortality between 
uncross matched and cross-
matched blood, number of 
products transfused 
 
FWB  
 
+ RBC + FFP 
RBC + FFP 
No statistical difference for unadjusted in-
hospital mortality between FWB (5.3%) & BCT 
(8.8%) (p value not reported) 
 
FWB were less likely to die vs BCT  
continuous variable logistic regression analysis  
OR 0.096, 95% CI 0.02-0.53 (p=0.008)  
stratified propensity score analysis  
OR 0.11, 95% CI 0.02-0.78 (p=0.03) 
 
FWB patients received significantly more units of 
RBC (12.7 vs 4.7, p=<0.001) and FFP (10 vs 2.6, 
p=<0.001) 
FWB patients were more likely to receive MBT 
(52.1% vs 11.6%, p=<0.001) 
 
No statistical difference in those who received 
type specific FWB or uncrossmatched FWB 
LOW 
⊕⊕ 
Yazer et 
al. (2016) 
 
(8) 
192 
Male patients 
attending a level 1 
trauma centre with 
hypotension 
secondary to 
bleeding who 
received at least 
one unit of WB 
compared to 
historical controls  
Primary: Haemolysis 
(haptoglobin used as marker) 
and transfusion reactions 
 
Secondary: Transfusion 
volumes, mortality rates (no 
additional information available) 
WB  
(up to 2 unit, 
leukoreduced)  
 
+ RBC + plasma 
+ PLT + cryo 
RBC + plasma 
+ PLT + cryo 
No statistical difference in mortality between 
the groups (WB 36% vs BCT 28%, p=0.27) 
 
No statistical difference between the number of 
blood products received by each group 
 
Median haptoglobin concentration on post-WB 
transfusion day 1 was 25.1mg/dL (normal) 
 
No transfusion reactions in the WB group 
VERY LOW 
⊕ 
Table 4 Summary of findings  
(BCT = blood component therapy; mWB = modified whole blood; WB = whole blood; FWB = fresh whole blood; WFWB = warm fresh whole blood; aPLT = apheresis platelets; RBC = red blood 
cells; FFP = fresh frozen plasma; cryo = cryoprecipitate; ISS = injury severity score; hr = hours; d = days; ARDS = acute respiratory distress syndrome; AKI = acute kidney injury; MODS = 
multiple organ dysfunction syndrome; MBT = massive blood transfusion ≥ 10units) 
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DISCUSSION     
This systematic review evaluated current evidence comparing whole blood 
transfusion with component therapy in adult trauma patients with acute major 
haemorrhage. There were only six studies, and overall quality was low.  Of 
the three studies reporting our primary outcome of 30-day mortality (total of 
830 patients) two had ratings for GRADE of Evidence of low and very low.(29, 
30) The highest quality evidence for this outcome was an RCT (GRADE of 
evidence moderate) which demonstrated no statistical difference in 30-day 
mortality; however this study (n=107) was not powered to demonstrate a 
difference in 30-day mortality as the primary outcome.(31) Two observational 
studies reporting in-hospital mortality (2233 patients)  found in logistic 
regression analyses that patients receiving WB transfusion strategy were less 
likely to die. (25, 26) However, both studies suffered from poor quality 
evidence with GRADE rated low and very low.  
 
In the studies conducted in military settings it is reported to take 30-45 
minutes to receive the first unit of WB, introducing survival bias favouring the 
patient group receiving WB. Rapidly exsanguinating patients may not survive 
long enough to receive WB. Only one study attempted to minimise this bias by 
excluding patients who died within the first hour of treatment.(26) It is 
important to note this issue will not be resolved with more retrospective 
studies. 
 
With WB not currently available in most civilian Western institutions, clinicians 
have adapted to the use of available component therapy. Interestingly, this 
practice now resembles reconstituted WB with component therapy transfused 
in a ratio of 1:1:1, after a multicentre observational study reported a reduction 
in mortality with higher plasma and platelet ratios (32). This was followed by 
an RCT demonstrating a trend toward survival in the group receiving 1:1:1 
regimen compared to 1:1:2.(16) A recent secondary analysis of a multicentre 
randomised phase III trial reported combined red blood cells and plasma 
transfusion had the greatest statistical reduction in 30-day mortality (HR 0.28, 
p=<0.001), compared to plasma or red blood cells or crystalloid alone 
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resuscitation.(18) It should however be noted that even between trauma 
centres there is a significant variation in practice and the regimen used.(33) 
 
Looking at adverse events between groups, one study (n= 354) reported a 
higher incidence of AKI in the WB group compared with component 
therapy.(30) Another study (n=369) found a higher incidence of ARDS in the 
FWB group compared to aPLT group.(29) Neither study was designed to 
address these measures as their primary outcome, and therefore may not be 
powered to demonstrate an accurate difference. Both studies used non-
leucoreduced fresh WB. Both AKI and ARDS may be the result of complex 
immunologic mechanisms. A simplified explanation includes inflammation 
caused by the transfusion of donor white blood cells.(30) White blood cells 
cause inflammation resulting from microvascular damage to the endothelium. 
In the lungs, this may cause vascular leakage into the alveolar space, 
resulting in pulmonary oedema and ARDS. Of note, most WB in the 
developing world is leucoreduced due to risk of infectious diseases such as 
variant Creutzfeldt-Jakob disease. 
 
The resuscitation end points for patients with TBI differ quite significantly from 
those with acute major haemorrhage. Patients with TBI require a higher mean 
arterial pressure to maintain cerebral perfusion pressure and are not generally 
resuscitated with all damage control resuscitation principles including 
permissive hypotension. The sub-analysis of patients with TBI suggests that if 
TBI patients are excluded from analysis due to the differing resuscitation 
goals, there is trend towards whole blood significantly reducing the transfusion 
volumes required.(31) However, due to the studies not being powered 
sufficiently this is an area that requires further research.  
 
Around a quarter to third of trauma patients requiring transfusion are 
coagulopathic at presentation.(13, 34) Presence of trauma-induced 
coagulopathy is an independent predictor of mortality.(35) WB is a more 
concentrated transfusion, reducing the total dilutional, non-haemostatic fluid 
transfused into a trauma patient. Therefore, WB may be superior compared to 
component therapy for reversing the effects of trauma-induced coagulopathy. 
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Whilst fresh WB transfusion is becoming increasingly established in the 
military setting, there are significant practical limitations to its application in the 
civilian healthcare system. The mobilisation of donors and collection is 
resource intensive, safety testing is time consuming, and most importantly 
fresh WB has a short shelf-life of up to 72 hours.(36) However there are 19 
trauma centres using WB in the United States (37), and civilian use of WB in 
the context of trauma and massive transfusion is being studied.(38-40) 
 
Limitations 
The quality of this systematic review is limited by methodology of the studies it 
appraises. The papers were mostly retrospective cohort studies with one 
prospective randomised trial. There was a paucity of high quality evidence. 
This systematic review is also limited by the significant heterogeneity of 
included studies. Both intervention and control groups are not consistent 
across studies. For example, one study compared leucoreduced mWB (no 
native platelet function), with the addition of 1 pool of apheresis platelets for 
every 6 units of mWB.(31) Another used non-leucoreduced WFWB with red 
blood cells and plasma.(30) These differences in transfusion protocol, 
comparison groups and outcome measures across studies meant that data 
pooling and meta-analysis were not possible.  
 
 
CONCLUSION   
Overall this systematic review is unable to determine if the use of WB 
transfusion compared with component therapy improves survival at 30-days in 
adult trauma patients with acute major haemorrhage based on the evidence 
identified. However, no reduction in survival was reported with WB transfusion 
in any of the included studies. Larger prospective, randomised or adaptive 
trials are required to better understand if WB improves survival. If the use of 
WB is shown to be superior to component therapy, blood services are more 
likely to manufacture WB despite the shorter shelf life. 
 
There were no sources of funding for this systematic review. 
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